Partnership Opportunities CID-103 IND clearance and the ongoing Phase 1 program position CASI for co development or licensing deals with larger biopharma seeking transplant and autoimmune franchises. The company has showcased data at the ASH meeting and is pursuing multiple indications, presenting BD opportunities to outreach to transplant centers, immunology networks, and potential licensing partners to accelerate development and share risk.

Trial Services With a Phase 1 dose ranging safety study in AMR, CASI will need CRO partners, clinical operations support, regulatory consultants, and data management to run trials efficiently. Opportunities exist to offer end to end trial outsourcing, investigator initiated studies, patient recruitment services, site management, and pharmacovigilance partnerships.

Manufacturing Readiness CID-103 as a monoclonal antibody requires GMP manufacturing and robust supply chain readiness. CASI may seek contract manufacturing organizations for process development, scale up, fill finish, quality control, and cold chain distribution planning for multi country trials and potential commercialization.

Funding Strategy Current revenue is in the tens of millions with modest funding on hand, suggesting a need for additional capital to advance late stage trials. Sales opportunities include partnering licenses, co development agreements, non dilutive funding and potential equity investments, especially leveraging new independent directors to attract investors.

Market Positioning CID-103 is positioned as potentially best in class and has data presented at ASH, creating opportunities to target organ transplant programs and autoimmune disease specialists. BD outreach should leverage digital tools and KOL engagement, conference follow ups, and investor communications, aligning with leadership changes to support strategic partnerships.